On September 3, 2024, Arthur Ryan, Director at Regeneron Pharmaceuticals Inc (REGN, Financial), executed a sale of 100 shares of the company at a price of $1178.69 per share. This transaction was reported in a recent SEC Filing. Following this sale, the insider now owns 17,682 shares of Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc (REGN, Financial) is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets products for eye diseases, high LDL cholesterol, and inflammatory diseases among others, and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases.
Over the past year, Arthur Ryan has sold a total of 1,100 shares of the company and has not made any purchases. The insider transaction history for Regeneron Pharmaceuticals Inc shows a pattern of 65 insider sells and no insider buys over the past year, indicating a trend of insider sales.
Shares of Regeneron Pharmaceuticals Inc were trading at $1178.69 on the day of the transaction, giving the company a market cap of approximately $126.83 billion. The price-earnings ratio of the stock is 30.47, which is above both the industry median of 25.68 and the company’s historical median.
According to the GF Value, the intrinsic value estimate for Regeneron Pharmaceuticals Inc is $768.39 per share, making the stock significantly overvalued with a price-to-GF-Value ratio of 1.53.
This sale by the insider at Regeneron Pharmaceuticals Inc aligns with the broader trend of insider sales at the company, suggesting that insiders might perceive the stock’s current valuation as high relative to its intrinsic value.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
